肺癌治疗市场 - 全球行业规模、份额、趋势、机会、预测，2018-2028 按癌细胞类型（非小细胞肺癌、小细胞肺癌）、治疗、地区划分

全球肺癌治疗市场预计在预测期内将出现显着增长。 推动市场增长的因素是肺癌发病率的增加和与肺癌相关的先进治疗方法。

肺癌患病率增加

肺癌（包括小细胞癌和非小细胞癌）是全球第二大常见癌症。 根据美国癌症协会对 2022 年肺癌的估计，美国将有大约 236,740 名（117,910 名男性；118,830 名女性）肺癌新病例，以及大约 88,820 名女性和 60,130 名女性）死于肺癌。 此外，据估计，男性肺癌的终生患病率为 1/15，女性为 1/17。 这个数字包括吸烟者和非吸烟者。

对免疫疗法的需求不断增长

药物、疫苗和其他刺激免疫系统自然防御以对抗癌症的疗法被称为免疫疗法。 一类称为“抗 PD-1”的免疫治疗剂已被证明可在 25% 的化疗后患者中引起显着的肿瘤消退。 三种免疫治疗药物——pembrolizumab、atezolizumab 和 nivolumab——被批准用于治疗某些非小细胞肺癌。 此外，多个组织正在资助免疫疗法研究，这有望促进市场扩张。 例如，2022 年，帕剋癌症免疫治疗研究所与科学家和商业先驱合作，创造了一种革命性的癌症免疫治疗药物。 因此，增加对免疫疗法的投资和采用正在推动全球肺癌治疗市场的需求。

癌症治疗的副作用

肺癌是一种慢性病，需要长期治疗。 这些治疗通过高剂量和长时间接触药物来影响人体。 与抗癌药物相关的常见副作用包括呼吸问题、疲劳、感染、出血、贫血、胃肠道问题（噁心、呕吐、腹泻、便秘）、外貌变化和脱髮。 例如，化疗会攻击癌细胞，但也会影响毛囊、血液、口腔和消化系统等健康细胞。 此外，副作用因人而异，用于治疗癌症的剂量也因人而异。 因此，癌症治疗的副作用预计会阻碍市场增长。

近期发展

• 2019 年 3 月，AdoRx Treatments Limited 宣布与 Johnson & Johnson Innovation LLC 和 Johnson & Johnson (LCI) Lung Cancer Initiative 结成战略联盟，以开发一种全新的创新型肺癌药物。

可自定义

根据市场数据，TechSci Research 根据公司的具体需求提供定制服务。 该报告可以定制为：

公司信息

• 对其他市场参与者（最多 5 家公司）进行深入分析和概况分析。

内容

第一章服务概述

• 市场定义
• 市场范围
  • 目标市场
  • 研究目标年份
  • 主要市场细分

第二章研究方法论

• 调查目的
• 基线调查方法
• 主要行业合作伙伴
• 主要协会和次要信息
• 调查方法
• 数据三角测量和验证
• 假设和限制

第 3 章执行摘要

• 市场概览
• 主要市场细分概述
• 主要市场参与者概览
• 主要地区/国家概览
• 市场驱动因素、挑战和趋势概述

第 4 章 VOC（客户之声）

第五章肺癌药物全球市场展望

• 市场规模和预测
  • 按金额
• 市场份额和预测
  • 按癌细胞类型（非小细胞肺癌 (NSCLC)、小细胞肺癌 (SCLC)）
  • 按治疗方法（化学疗法、放射疗法、免疫疗法、靶向疗法、其他治疗方法）
  • 按地区
  • 按公司分类（2022 年）
• 市场地图
  • 按癌细胞类型
  • 通过治疗

第六章北美肺癌药物市场展望

• 市场规模和预测
  • 按金额
• 市场份额和预测
  • 按癌细胞类型（非小细胞肺癌 (NSCLC)、小细胞肺癌 (SCLC)）
  • 按治疗方法（化学疗法、放射疗法、免疫疗法、靶向疗法、其他治疗方法）
  • 按国家
• 北美：国家/地区分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲肺癌药物市场前景

• 市场规模和预测
  • 按金额
• 市场份额和预测
  • 按癌细胞类型（非小细胞肺癌 (NSCLC)、小细胞肺癌 (SCLC)）
  • 按治疗方法（化学疗法、放射疗法、免疫疗法、靶向疗法、其他治疗方法）
  • 按国家
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 意大利
  • 西班牙

第八章亚太地区肺癌药物市场展望

• 市场规模和预测
  • 按金额
• 市场份额和预测
  • 按癌细胞类型（非小细胞肺癌 (NSCLC)、小细胞肺癌 (SCLC)）
  • 按治疗方法（化学疗法、放射疗法、免疫疗法、靶向疗法、其他治疗方法）
  • 按国家
• 亚太地区：国家/地区分析
  • 中国
  • 日本
  • 印度
  • 韩国
  • 澳大利亚

第9章南美肺癌药物市场展望

• 市场规模和预测
  • 按金额
• 市场份额和预测
  • 按癌细胞类型（非小细胞肺癌 (NSCLC)、小细胞肺癌 (SCLC)）
  • 按治疗方法（化学疗法、放射疗法、免疫疗法、靶向疗法、其他治疗方法）
  • 按国家
• 南美洲：：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章中东和非洲肺癌药物市场展望

• 市场规模和预测
  • 按金额
• 市场份额和预测
  • 按癌细胞类型（非小细胞肺癌 (NSCLC)、小细胞肺癌 (SCLC)）
  • 按治疗方法（化学疗法、放射疗法、免疫疗法、靶向疗法、其他治疗方法）
  • 按国家
• MEA：国家分析
  • 阿联酋肺癌药物
  • 沙特阿拉伯肺癌药物
  • 南非肺癌药物
  • Turkiye 肺癌药物
  • 埃及肺癌药物

第 11 章市场动态

• 主持人
  • 肺癌患病率上升
  • 吸烟人数增加
  • 对免疫疗法的需求不断增长
• 做
  • 昂贵的癌症治疗费用
  • 关于药物的副作用
  • 缺乏技术工人

第12章市场趋势与发展

• 产品发布
• 併购
• 技术进步

第13章临床试验分析

第 14 章全球肺癌药物市场：SWOT 分析

第15章竞争格局

• 业务概览 提供的产品 近期发展 财务状况（针对上市公司） 关键人员 SWOT 分析
• • AstraZeneca Plc
  • Boehringer Ingelheim International GmbH.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co
  • Pfizer Inc.
  • Allergan Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Abbvie, Inc.
  • Johnson & Johnson
  • Amgen Inc.
  • Novartis AG

第16章 策略建议

The global lung cancer therapeutics market is projected to witness impressive growth during the forecast period. The factors contributing to the growth of the market are the increasing incidence of lung cancer and sophisticated treatments associated with lung cancer.

Lung cancer therapeutics is a branch of medicine concerned with the treatment of lung cancer, which includes radiation therapy, chemotherapy, targeted therapy, immunotherapy, and others. The treatment also includes the adoption of personalized medicines to increase the rate of survival in terms of the high proliferation of cancer cells in the lungs.

The introduction of nanomedicines to treat lung cancer and regulatory approvals of medicines is expected to drive the growth of the market during the forecast period. Further, a surge in lung cancer prevalence and the dominance of chemotherapy are driving the growth of the market during the forecast period.

Increasing Prevalence of Lung Cancer

Lung cancer (both small cell and non-small cell) is the second most common cancer globally. As per the American Cancer Society's estimates for lung cancer in 2022, approximately 236,740 new cases of lung cancer (117,910 in men and 118,830 in women) were reported in the US, and about 130,180 (68,820 men and 61,360 women) people died due to lung cancer. Further, the overall chances of lung cancer prevalence in a man for a lifetime period are 1 in 15, and for women, the risk is about 1 in 17. This number includes smokers as we non-smokers.

The rise in demand for Immunotherapy

The use of medications, vaccinations, and other therapies to stimulate the immune system's natural defenses so that it can combat cancer is known as immunotherapy. One class of immunotherapy medication known as "anti-PD-1" has been demonstrated to result in significant tumor regression in 25% of patients who get it after a round of chemotherapy. Three immunotherapy drugs-pembrolizumab, atezolizumab, and nivolumab have been approved to treat certain non-small cell lung cancers. Additionally, several organizations are funding immunotherapy research, which is anticipated to boost market expansion. For instance, in 2022, to create innovative immunotherapy medicines for cancer, the Parker Institute for Cancer Immunotherapy collaborated with scientists and business pioneers. Hence, rising investment and adoption of immunotherapy are fueling the demand for the global lung cancer therapeutics market.

Side Effects of cancer treatment

Lung cancer is a chronic disease with lengthy treatments. These treatments affect the human body due to high and long exposure to drugs. Some of the common side effects related cancer curing drugs include breathing problems, fatigue, infection, bleeding, anemia, Stomach problems (nausea, vomiting, diarrhea, or constipation), changes in appearance, hair fall, and others. For instance, Chemotherapy attacks cancer cells, but it also impacts some healthy cells in the hair follicles, blood, mouth, and digestive system. Moreover, side effects vary from person to person and the dose used to treat cancer. Hence, the side effects of cancer treatment are projected to hamper the growth of the market.

Market Segmentation

The global lung cancer therapeutics market is segmented based on cancer cell type, treatment, region, and company. Based on Cancer Cell Type, the market is categorized into Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC). Based on Treatment, the market is segmented into Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, and Other Treatments.

Recent Developments

• In March 2019, AdoRx Treatments Limited announced a strategic alliance with Johnson & Johnson Innovation LLC and the Lung Cancer Initiative at Johnson & Johnson (LCI) for the creation of brand-new, innovative lung cancer therapeutics.

Market Players

AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Merck & Co, Pfizer Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd., Abbvie, Inc., Johnson & Johnson, Amgen Inc., Novartis AG among others are the major players in the Global Lung Cancer Therapeutics Market.

Report Scope

In this report, the global lung cancer therapeutics market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Lung Cancer Therapeutics Market, By Cancer Cell Type:

• Non-small Cell Lung Cancer (NSCLC)
• Small Cell Lung Cancer (SCLC)

Lung Cancer Therapeutics Market, By Treatment:

• Chemotherapy
• Radiation Therapy
• Immunotherapy
• Targeted Therapy
• Other Treatments

Lung Cancer Therapeutics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico

• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain

• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia

• South America
  • Brazil
  • Argentina
  • Colombia

• Middle East & Africa
  • UAE
  • Saudi Arabia
  • South Africa
  • Turkey
  • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Lung Cancer Therapeutics Market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Service Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Lung Cancer Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC))
  • 5.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
  • 5.2.3. By Region
  • 5.2.4. By Company (2022)
• 5.3. Market Map
  • 5.3.1. By Cancer Cell Type
  • 5.3.2. By Treatment

6. North America Lung Cancer Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
  • 6.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Lung Cancer Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Cancer Cell Type
      • 6.3.1.2.2. By Treatment
  • 6.3.2. Canada Lung Cancer Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Cancer Cell Type
      • 6.3.2.2.2. By Treatment
  • 6.3.3. Mexico Lung Cancer Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Cancer Cell Type
      • 6.3.3.2.2. By Treatment

7. Europe Lung Cancer Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
  • 7.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Lung Cancer Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Cancer Cell Type
      • 7.3.1.2.2. By Treatment
  • 7.3.2. Germany Lung Cancer Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Cancer Cell Type
      • 7.3.2.2.2. By Treatment
  • 7.3.3. United Kingdom Lung Cancer Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Cancer Cell Type
      • 7.3.3.2.2. By Treatment
  • 7.3.4. Italy Lung Cancer Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Cancer Cell Type
      • 7.3.4.2.2. By Treatment
  • 7.3.5. Spain Lung Cancer Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Cancer Cell Type
      • 7.3.5.2.2. By Treatment

8. Asia-Pacific Lung Cancer Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
  • 8.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Lung Cancer Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Cancer Cell Type
      • 8.3.1.2.2. By Treatment
  • 8.3.2. Japan Lung Cancer Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Cancer Cell Type
      • 8.3.2.2.2. By Treatment
  • 8.3.3. India Lung Cancer Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Cancer Cell Type
      • 8.3.3.2.2. By Treatment
  • 8.3.4. South Korea Lung Cancer Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Cancer Cell Type
      • 8.3.4.2.2. By Treatment
  • 8.3.5. Australia Lung Cancer Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Cancer Cell Type
      • 8.3.5.2.2. By Treatment

9. South America Lung Cancer Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
  • 9.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Lung Cancer Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Cancer Cell Type
      • 9.3.1.2.2. By Treatment
  • 9.3.2. Argentina Lung Cancer Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Cancer Cell Type
      • 9.3.2.2.2. By Treatment
  • 9.3.3. Colombia Lung Cancer Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Cancer Cell Type
      • 9.3.3.2.2. By Treatment

10. Middle East and Africa Lung Cancer Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Cancer Cell Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
  • 10.2.2. By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Other Treatments)
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. UAE Lung Cancer Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Cancer Cell Type
      • 10.3.1.2.2. By Treatment
  • 10.3.2. Saudi Arabia Lung Cancer Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Cancer Cell Type
      • 10.3.2.2.2. By Treatment
  • 10.3.3. South Africa Lung Cancer Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Cancer Cell Type
      • 10.3.3.2.2. By Treatment
  • 10.3.4. Turkey Lung Cancer Therapeutics Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Cancer Cell Type
      • 10.3.4.2.2. By Treatment
  • 10.3.5. Egypt Lung Cancer Therapeutics Market Outlook
    • 10.3.5.1. Market Size & Forecast
      • 10.3.5.1.1. By Value
    • 10.3.5.2. Market Share & Forecast
      • 10.3.5.2.1. By Cancer Cell Type
      • 10.3.5.2.2. By Treatment

11. Market Dynamics

• 11.1. Drivers
  • 11.1.1. Increasing Prevalence of Lung Cancer.
  • 11.1.2. Rise in the number of Tobacco Smokers
  • 11.1.3. Rise in demand for Immunotherapy
• 11.2. Challenges
  • 11.2.1. High Cost of Cancer Treatment
  • 11.2.2. Side Effects of Drugs
  • 11.2.3. Lack of skilled workforce

12. Market Trends & Developments

• 12.1. Product Launches
• 12.2. Mergers & Acquisitions
• 12.3. Technological Advancements

13. Clinical Trial Analysis

14. Global Lung Cancer Therapeutics Market: SWOT Analysis

15. Competitive Landscape

• 15.1. Business Overview
• 15.2. Product Offerings
• 15.3. Recent Developments
• 15.4. Financials (In Case of Listed Companies)
• 15.5. Key Personnel
• 15.6. SWOT Analysis
  • 15.6.1. AstraZeneca Plc
  • 15.6.2. Boehringer Ingelheim International GmbH.
  • 15.6.3. Bristol-Myers Squibb Company
  • 15.6.4. Eli Lilly and Company
  • 15.6.5. F. Hoffmann-La Roche Ltd.
  • 15.6.6. Merck & Co
  • 15.6.7. Pfizer Inc.
  • 15.6.8. Allergan Inc.
  • 15.6.9. Teva Pharmaceutical Industries Ltd.
  • 15.6.10. Abbvie, Inc.
  • 15.6.11. Johnson & Johnson
  • 15.6.12. Amgen Inc.
  • 15.6.13. Novartis AG

16. Strategic Recommendations